ACCCBUZZ BLOG

Oncology Hematology Care, Inc. launched a one-year quality improvement project to implement and standardize comprehensive biomarker testing in patients with metastatic non-small cell lung cancer.

For patients with pancreatic cancer, clinical trials should be considered as a possible treatment option early on, not a last resort when all else fails. The Let's Win team discusses why.

ACCC set out to identify and understand specific regional challenges to appropriate and equitable care for patients with chronic lymphocytic leukemia, the most common form of leukemia in adults.

Let’s Win Pancreatic Cancer is an advocacy organization that works with patients, providers, and researchers to share the latest information and treatment options for pancreatic cancer.

ACCCBuzz spoke with Erika Siegrist at Luminis Health Research Institute to learn more about how technology has helped expand patient access to cancer clinical trials.

As efforts to promote health equity continue to grow, educating patients with cancer about the importance of clinical trials and cancer screenings is of the utmost importance.

At the 2023 National Minority Quality Forum Summit on Health Disparities and Spring Health Braintrust, panelists discussed strategies that can be implemented to improve diversity in clinical trials.

Before opening the ACCC 49th Annual Meeting & Cancer Center Business Summit to its membership, ACCC held two pre-conference events on Wednesday, March 8. Learn more about what was discussed among invited speakers during these events.

For 2023, ACCC members have identified four core areas of focus (e.g., reimbursement, utilization management, provider-patient choice), among a larger set of issues and concerns, that the association will be supporting this year.

Dr. Kevin Davies previews his opening keynote at the upcoming Association of Community Cancer Centers (ACCC) 49th Annual Meeting & Cancer Center Business Summit (AMCCBS).

November 13 to 19 is dedicated to National Nurse Practitioner Week, and the Association of Community Cancer Centers (ACCC) is taking this opportunity to recognize its nurse practitioner (NP) members—highlighting the work NPs do to improve access to care, the patient and clinician experience, and patient outcomes.

ACCC President Dr. David Penberthy, honors the 2022 ACCC Award winners for their significant contributions to the oncology community. Speakers share key strategies to enhance the role of the oncology pharmacist and prepare for population health in oncology.

The ACCC 39th National Oncology Conference opened with two pre-conferences, covering financial advocacy in oncology and the future of cancer care. Learn what care delivery may look like in 2040 and how ACCC is supporting cancer programs and practices through its Financial Advocacy Network.

Tom Vibert was diagnosed with Stage 4 metastatic colon cancer in 2014. Learn how participating in a clinical trial allowed Vibert to get back on the bike and beat his cancer.

Advocating on behalf of their patients and programs, ACCC members from 14 states participated in Virtual Hill Day, speaking with Congress and their staff on key legislation asks regarding access to care, telehealth, prior authorizations, and more.

ACCC has partnered with several of its oncology state societies to establish the Appalachian Community Cancer Alliance—a key effort to address disparities in cancer screening and care delivery in the region.

The second post in a three-blog series, ACCCBuzz shares how Carolina Blood and Cancer Care Associates' NOLA initiative is addressing access to care, clinical trials, biomarker testing, and more.

Carolina Blood and Cancer Care Associate's No One Left Alone (or NOLA) initiative is a multi-phase pilot program aimed at lessening disparities in cancer care in three key areas: care access, biomarker testing, and clinical trials.

In 2021, ACCC launched the ACCC Community Oncology Research Institute (ACORI), which builds on ACCC’s mission to achieve equitable cancer care for all patients by forming key community partnerships. As part of this mission, ACCC hosted the ACORI Call to Action Summit, a two-day virtual event held September 13-14, 2021, to garner participant feedback and guide the future of the institute.

Although clinical trials have been used for decades to determine the safety and efficacy of drugs and medical devices, the lack of a diverse population in such studies has failed to represent the population suffering the burden of the diseases being studied.

The U.S. Food and Drug Administration's Oncology Center of Excellence, Project Community, has designated June 17 to June 23 as National Black Family Cancer Awareness Week. The week coincides with Juneteenth—an important date in our nation’s history that marks and celebrates the end of slavery in the United States. By participating in the #BlackFamCan social media effort, ACCC is building support and sharing knowledge with key stakeholders about the importance of including Black patients in cancer clinical trials and genetic databases for oncology research to improve access and effect change in cancer care delivery.

As City of Hope embarkes on the development of an experimental COVID-19 vaccine currently in a phase I clinical trial, ACCCBuzz spoke with Dr. Sanjeet Dadwal about the investigational vaccine’s safety and efficacy, potential emergency use authorization (EUA), and suitability for patients with cancer.

Older adults with cancer are consistently precluded from participating in clinical trials for promising new treatments. A multi-pronged approach is required to ensure trials are developed for all patients, including paying specific attention to inclusion/exclusion criteria and creating clinically meaningful endpoints that can enhance enrollment efforts in underserved populations.

The disparities in prostate cancer are striking. In the United States, Black men continue to experience a far greater incidence of new prostate cancers and are 2.2 to 2.5 times more likely to die from the disease than any other racial/ethnic group. Taking action to close these gaps is an imperative for moving toward equitable cancer care.